Newcelx Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Newcelx Ltd. on August 3, 2026, for the month of August 2026. The filing discloses a definitive private placement financing agreement entered into on July 31, 2026, with certain accredited investors.
Key Financial Metrics
- Gross Proceeds: Expected to be approximately $1.4 million from the initial purchase of 347,134 common shares or pre-funded warrants at $4.033 per share.
- Potential Additional Proceeds: Approximately $1.5 million if common warrants to purchase up to 347,134 shares at $4.437 per share are fully cash-exercised.
- Existing Liquidity: The Company references a previously announced $25 million equity line and its current cash position.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Debt: The filing text does not provide a clear value for outstanding debt.
Material Changes
The primary material change is the execution of the securities purchase agreement for the private placement. The Company has agreed to a 60-day lock-up period, during which it cannot issue or announce the issuance of common shares or equivalents, subject to customary exceptions. Additionally, the Company must file a registration statement for the resale of the securities within 45 calendar days of the agreement date.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds, combined with current cash and the $25 million equity line, will primarily advance NCEL-101, the lead program for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes.
- Closing Conditions: The offering is expected to close on or about August 14, 2026, subject to customary closing conditions. If conditions are not met, the offering may not close.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the timing and completion of the offering and the use of proceeds, which are not guaranteed.
- Regulatory Status: Securities are sold under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D and are not registered under the Securities Act.
Investor Verification Checklist
- Verify the final closing date of the private placement, currently expected on or about August 14, 2026.
- Confirm the actual amount of net proceeds received after deducting transaction costs.
- Monitor the filing of the registration statement for resale of shares, required within 45 days of July 31, 2026.
- Review the status of the $25 million equity line and current cash position to assess total liquidity.
- Track the progress of the NCEL-101 program for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals.